A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
ConditionEwing Sarcoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age12-18
SponsorBeijing Konruns Pharmaceutical Co., Ltd.
About this trial
This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.
Eligibility criteria
Qualifiers
Age between 12 and less than 18 years;
Diagnosed with Ewing sarcoma confirmed by histopathological examination;
Patients with locally advanced or metastatic Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator;
Body weight of ≥30 kg;
Disqualifiers
Patients with primary central nervous system tumors;
Presence of central nervous system metastases as diagnosed by imaging;
History of or concurrent other malignancies within the past 5 years;
Gastrointestinal abnormalities;
Trial design
Treatments tested in this trial
- KC1036
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov